|
Climax Control
Product Reviews
|
 
Taboo No Longer--The Changing Attitudes Towards Erectile Dysfunction
by D. Cannon
One little blue erectile dysfunction pill changed the world for millions of men who had previously been suffering from ED in silence. Viagra, the trade name of the drug sildenafil which was first successfully manufactured and distributed by pharmaceutical giant Pfizer, is not only an effective medical treatment for ED, it has also become a pop culture icon. Sildenafil was originally created to treat angina, high blood pressure, and similar cardiovascular disorders. When the drug entered its clinical trial phase, it was discovered that it had very little effect in treating its target disorders, but many of the participants in the trial noticed a rather unmistakable side effect--the drug was inducing rather pronounced penile erections. Correctly sensing that they had stumbled on to a goldmine, Pfizer quickly changed course and released Viagra as the first approved medical treatment for ED in 1996. Since then, several other companies have released their own ED treatments, most notably Cialis by Eli Lilly and Company and Levitra by Bayer. There have also been numerous herbal and other nontraditional ED treatments that have attempted to ride the coat tails of Viagra.
The first step in treating ED is determining the true cause of the disorder. Typically, when someone first discusses erectile difficulties with their physician, the doctor will endeavor to rule out any undetected diseases that may be triggering the condition. Diabetes is a common culprit of erectile difficulties, as are certain cardiovascular conditions. If an underlying physical condition can not be found, the physician may either recommend a round of counseling in order to discover whether or not there may be some underlying psychological condition or he or she may go ahead and prescribe an erectile dysfunction drug.
D. Cannon writes on a variety of subjects and recommends http://www.diseaseinforx.com for more information on the subject.
|
|
|
|
|
